– UK, Brentford – GSK plc (LON: GSK | NYSE: GSK) today announced the appointment of Liz McKee Anderson to its Board as a Non-Executive Director with effect from 1 September 2022.
“I am delighted to welcome Liz to GSK. Her significant experience in commercial biopharmaceuticals, both operationally and at the Board level, as well as her deep understanding of the biotechnology sector, will be invaluable to GSK as we begin our next chapter as a 100% focused biopharma company.” said Board chair, Sir Jonathan Symonds.
The company also confirmed the retirement of Laurie Glimcher from the Board on 13 October 2022.
About Elizabeth McKee Anderson
Liz brings significant experience in commercial biopharmaceuticals and is a seasoned biotech board member. She previously served as Worldwide VP and commercial leader in infectious diseases and vaccines, immunology, and oncology at Janssen Pharmaceuticals, and as VP and GM at Wyeth Vaccines. Liz is currently a Board member of; BioMarin Pharmaceuticals, Revolution Medicines, Inc., Insmed, Inc., and Aro Biotherapeutics Company. She was also previously a Board member of Bavarian Nordic A/S and Huntsworth Plc. Liz also serves on the Board of Trustees of The Wistar Institute, a leading biomedical research organization in the US.
About GSK
GSK is a global biopharma company to unite science, technology, and talent to get ahead of disease together.
For more information: https://www.gsk.com/en-gb/home/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.